Real-World Validation That Drives Reimbursement
​
Statistics show that 95% of AI pilot projects fail, not because the technology lacks promise, but because they validate features, not value. At Strategic Growth AI, we design and co-execute lean, 3–6 month pilot projects that generate the precise evidence payers, providers, and investors require to say “yes” at scale.
​
Our pilots are not tech demos. They are strategic proof-generation engines built around three pillars: (1) payer-aligned outcomes (e.g., reduced readmissions, faster diagnosis, cost-per-episode savings), (2) seamless workflow integration validated by frontline clinicians, and (3) real-world data collection that feeds directly into HEOR models, RWE frameworks, and CADTH/CMS reimbursement dossiers. Before launch, our AI-powered stakeholder mapping identifies clinical champions, procurement leads, and operational gatekeepers, securing institutional buy-in that cuts sales cycles in half and achieves 80% hospital engagement pre-commercialization.
​
Every pilot is tied to a kill/pivot/scale decision gate. Using SGAI Clarity Intelligence™, we monitor KPIs in near real-time—tracking patient adherence, clinician uptake, and claim adjudication patterns. If the data shows misalignment, we pivot. If it demonstrates compelling value, we scale with confidence. This prevents wasted spend on non-viable concepts and safeguards investor capital from the #1 cause of post-entry failure: launching into a market that won’t pay.
​
For diagnostics, digital therapeutics, SaMD, and AI-enabled medtech, this approach turns a beta into a strategic asset, one that not only validates technology but also accelerates coverage, drives adoption, and de-risks your full-scale go-to-market. In a world where 62% of launches underperform Wall Street expectations, our pilot-first model is your insurance policy against irrelevance.